AB SCIENCE |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.13 EUR | +1.43% |
|
+4.93% | -40.08% |
| 05-13 | AB Science: European patent granted for masitinib | CF |
| 05-03 | AB Science: upbeat after legal success | CF |
ETFs positioned on AB Science
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.
Sector
Pharmaceuticals
Calendar
29/09/2024
- Q2 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.1
EUR
Average target price
6.895
EUR
Spread / Average Target
+228.33%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -40.08% | 116M | |
| +14.57% | 74.45B | |
| +11.35% | 9.18B | |
| +60.16% | 5.03B | |
| -12.85% | 5.02B | |
| +1.60% | 3.82B | |
| -19.20% | 2.41B | |
| +18.99% | 2.39B | |
| -27.46% | 2.27B | |
| +24.62% | 2.26B |
- Stock Market
- Equities
- AB Stock
- Funds and ETFs AB Science
